作者
Thomas B Brunner, Matthias Geiger, Gerhard G Grabenbauer, Marga Lang-Welzenbach, Tine S Mantoni, Alexander Cavallaro, Rolf Sauer, Werner Hohenberger, W Gillies McKenna
发表日期
2008/6/1
期刊
Journal of Clinical Oncology
卷号
26
期号
16
页码范围
2699-2706
出版商
American Society of Clinical Oncology
简介
Purpose
Preclinically, HIV protease inhibitors radiosensitize tumors with activated PI3-kinase/Akt pathway. We determined the toxicity of nelfinavir chemoradiotherapy in borderline resectable and unresectable pancreatic cancer.
Patients and Methods
Oral nelfinavir (2 × 1,250 mg) was started 3 days before and continued throughout chemoradiotherapy to 50.4 Gy (boost, 59.4 Gy) in 12 patients. Two gemcitabine dose levels (DL) were tested (200 mg/m2 and 300 mg/m2 on days 1, 8, 22, and 29). Cisplatin was administered on the same days at 30 mg/m2. Phospho-Akt downregulation by nelfinavir was monitored by immunoblotting in patient leukocytes. Restaging positron emission tomography (PET)/computed tomography (CT) and CA19-9 levels served to assess response, and responding tumors were resected.
Results
At each DL, five of six patients completed …
引用总数
2008200920102011201220132014201520162017201820192020202120222023202441118161710112022134678511